Track topics on Twitter Track topics that are important to you
Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic bone disorder showed a nearly 90% reduction in new lesions compared to placebo, in a mid-stage study.
Original Article: Regeneron's bone disorder drug reduces lesions in mid-stage studyNEXT ARTICLE
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...